69. Identifying and Connecting Adolescent Patients to HIV Pre-Exposure Prophylaxis

Abstract

In the United States, approximately 34,800 people were diagnosed with HIV in 2019 and approximately 22% of those persons aged 13-24. HIV pre-exposure prophylaxis (PrEP), or use of antiretroviral medication for prevention of new HIV infection, has been a highly effective method of new HIV infection used in adults since 2012. In 2018, the FDA approved tenofivir disoproxil fumarate (TDF)/emtricitabine (FTC) for PrEP in adolescents weighing at least 35 kilograms and in 2019 expanded to include tenofivir alafenamide (TAF)/FTC for at-risk patients assigned male at birth.